WEST

Generate Collection

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: WO 200142445 A2

L5: Entry 1 of 2 File: DWPI Jun 14, 2001

DERWENT-ACC-NO: 2001-356173
DERWENT-WEEK: 200137
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Isolated infectious chimeric parainfluenza virus (PIV), useful in an attenuated vaccine to elicits an immune response against one or more virus(es) selected from human PIV1 (HPIV1), HPIV2 and HPIV3

INVENTOR: COLLINS, P L; DURBIN, A P ; MURPHY, B R ; SCHMIDT, A C ; SKIADOPOULOS, M H ; TAO, T

PRIORITY-DATA: 1999US-0459062 (December 10, 1999), 1999US-0170195 (December 10, 1999), 1999US-0458813 (December 10, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200142445 A2	June 14, 2001	E	305	C12N015/00

INT-CL (IPC): C12N 15/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 2. Document ID: AU 200056303 A, WO 200104320 A1

L5: Entry 2 of 2 File: DWPI Jan 30, 2001

DERWENT-ACC-NO: 2001-081053
DERWENT-WEEK: 200127
COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Isolated human-bovine chimeric parainfluenza virus (PIV), useful in an attenuated vaccine to elicits an immune response against one or more virus(es) selected from human PIV1 (HPIV1), HPIV2 and HPIV3

INVENTOR: BAILLY, J E; COLLINS, P L ; DURBIN, A P ; MURPHY, B R ; SCHMIDT, A C ; SKIADOPOULOS, M H

PRIORITY-DATA: 1999US-0143134 (July 9, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200056303 A	January 30, 2001		000	C12N015/45
WO 200104320 A1	January 18, 2001	E	148	C12N015/45

INT-CL (IPC): A61K 39/155; C07K 14/115; C12N 5/10; C12N 7/00; C12N 15/45

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Terms	Documents
chimeric parainfluenza	2

Database:
- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Refine Search: chimeric parainfluenza Clear

Search History

Today's Date: 11/2/2001

DB Name	Query	Hit Count	Set Name
DWPI	chimeric parainfluenza	2	L5
USPT	chimeric parainfluenza	0	L4
PGPB	Murphy .in.	34	L3
PGPB	Murphy B.in.	0	L2
PGPB	chimeric parainfluenza	0	L1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Generate Collection

Terms	Documents
chimeric parainfluenza	2

Display 10 Documents, starting with Document: 2

Display Format: CIT Change Format

WEST

End of Result Set

☐ Generate Collection

L5: Entry 2 of 2 File: DWPI Jan 30, 2001

DERWENT-ACC-NO: 2001-081053
DERWENT-WEEK: 200127

TITLE: Isolated human-bovine chimeric parainfluenza virus (PIV), useful in an attenuated vaccine to elicits an immune response against one or more virus(es) selected from human PIV1 (HPIV1), HPIV2 and HPIV3

INVENTOR: BAILLY, J E; COLLINS, P L ; DURBIN, A P ; MURPHY, B R ; SCHMIDT, A C ; SKIADOPOULOS, M H

PATENT-ASSIGNEE: US DEPT HEALTH & HUMAN SERVICES (USSH)

PRIORITY-DATA: 1999US-0143134 (July 9, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200056303 A	January 30, 2001		000	C12N015/45
WO 200104320 A1	January 18, 2001	E	148	C12N015/45

DESIGNATED-STATES: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
AU 200056303A	June 16, 2000	2000AU-0056303	
AU 200056303A		WO 200104320	Based on
WO 200104320A1	June 16, 2000	2000WO-US17066	

INT-CL (IPC): A61K 39/155; C07K 14/115; C12N 5/10; C12N 7/00; C12N 15/45

ABSTRACTED-PUB-NO: WO 200104320A
BASIC-ABSTRACT:

NOVELTY - An isolated human-bovine chimeric parainfluenza virus (PIV) that is infectious and attenuated in humans, is new.

DETAILED DESCRIPTION - An isolated human-bovine chimeric parainfluenza virus (PIV) that is infectious and attenuated in humans, is new.

The virus comprises a major nucleocapsid protein (N), a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a partial or complete PIV background genome, or antigenome of a human PIV (HPIV) or bovine PIV (BPIV), combined with one or more heterologous gene(s) or genome segment(s) of a different PIV to form a human-bovine chimeric PIV genome or antigenome.

INDEPENDENT CLAIMS are also included for the following:

(1) a method for stimulating the immune system of an individual to induce protection against PIV, comprising administering an immunologically sufficient

amount of the chimeric PIV;

(2) an isolated polynucleotide comprising a chimeric PIV genome or antigenome which includes a partial or complete PIV background genome or antigenome of a human or bovine PIV combined with a heterologous gene or genome segment of a different PIV to form a human-bovine chimeric PIV genome or antigenome;

(3) a method for producing an infectious attenuated chimeric PIV particle from one or more isolated polynucleotide molecules encoding the PIV, comprising expressing PIV N, P, and L proteins, and an expression vector comprising the polynucleotide of (2) in a cell or cell-free lysate; and

(4) an expression vector comprising an operably linked transcriptional promoter, the polynucleotide sequence of (2) and a transcriptional terminator.

ACTIVITY - Antiviral.

The rJS (wild-type HPIV3), Ka parent (Kansas BPIV3 strain), cKa (chimeric Ka strain), SF parent (Shipping fever BPIV3 strain) and cSF (chimeric SF strain) were administered intranasally and intratracheally at a dose of 100000 TCID50 per site to rhesus monkeys. Replication was monitored using standard procedures for obtaining samples from the upper (nasopharyngeal swab specimens) and lower (tracheal lavage specimens) respiratory tract and for titering the virus in LLC-MK2 cells. The cKa and cSF recombinants were significantly attenuated for the upper respiratory tract exhibiting, respectively, a 63-fold or a 32-fold reduction in mean peak virus titer compared to that of the rJS HPIV3 parent. Both cKa and cSF were also attenuated for the lower respiratory tract, but this difference was only statistically significant for cSF. The low level of replication of rJS in the lower respiratory tract made it difficult to demonstrate in a statistically-significant fashion further restriction of replication due to an attenuation phenotype at this site.

The level of replication of each chimeric virus, cKa and cSF, was not significantly different from its bovine parent in the upper or the lower respiratory tract, although the chimeric viruses each replicated better than their BPIV3 parents in the upper respiratory tract.

MECHANISM OF ACTION - Anti-PIV vaccine.

USE - The chimeric PIV is useful in an attenuated vaccine to elicits an immune response against one or more virus(es) selected from HPIV1, HPIV2 and HPIV3.

Preferably, the chimeric PIV elicits an immune response against HPIV3 and another virus selected from HPIV1, HPIV2 or HPIV3 (claimed).

ABSTRACTED-PUB-NO: WO 200104320A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/11

DERWENT-CLASS: B04 D16
CPI-CODES: B04-E02F; B04-E08; B04-F01; B04-F1100E; B14-A02B2; B14-G01; B14-S11A; D05-H07; D05-H12B2; D05-H12E; D05-H12F; D05-H14;